Berkeley HeartLab provides cardiovascular disease (CVD) management tools and services with a distinctive focus on the secondary prevention market. Unlike other lipid testing companies that are focused on the primary screening market for CVD, our proprietary testing technology enables risk characterization and uniquely allows for ongoing therapeutic monitoring of a patient's disease.

The Berkeley HeartLab high complexity CLIA-certified laboratory provides over 35 clinical diagnostic tests. Our comprehensive approach includes assays that determine lipoprotein particle size and density based on our proprietary segmented gradient gel electrophoresis technology and state-of-the-art genetic testing. These tests help clinicians identify and stratify risks and recommend treatment for cardiovascular disease with high levels of confidence. The cost to patients with the appropriate diagnoses is manageable, as Berkeley HeartLab tests may be reimbursed by private insurance and Medicare.

Our 4myheart Program staff of medical and clinical professionals uses the Berkeley HeartLab test results to customize each patient's education about nutrition, exercise, stress management and therapy adherence, pursuant to each clinician's treatment plan. Through our combination of proprietary lipid testing technology, esoteric testing capability, advanced therapy guidelines, sophisticated informatics tools, and patient support services, we provide clinicians and patients with a viable disease management offering for CVD prevention.